vimarsana.com

Latest Breaking News On - Longboard pharmaceuticals company profile - Page 1 : vimarsana.com

Longboard Pharmaceuticals' (LBPH) "Buy" Rating Reiterated at HC Wainwright

Longboard Pharmaceuticals' (LBPH) "Buy" Rating Reiterated at HC Wainwright
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird
Bourgeon-capital-management
Longboard-pharmaceuticals
Td-asset-management-inc
Citigroup
Longboard-pharmaceuticals-stock-performance
Denali-advisors
News-ratings-for-longboard-pharmaceuticals-daily
Analyst-recommendations-for-longboard-pharmaceuticals
Cantor-fitzgerald
Sg-americas-securities

HC Wainwright Reiterates "Buy" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

HC Wainwright Reiterates "Buy" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird
Citigroup
Bourgeon-capital-management
Longboard-pharmaceuticals
Sg-americas-securities
Cantor-fitzgerald
Longboard-pharmaceuticals-company-profile
Institutional-investors-weigh-in-on-longboard-pharmaceuticals
Longboard-pharmaceuticals-inc
Asset-management-inc
Longboard-pharmaceuticals-stock

Cantor Fitzgerald Reiterates "Overweight" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They currently have a $60.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the company’s current price. Other […]

Robertw-baird
Longboard-pharmaceuticals-stock-performance
Longboard-pharmaceuticals
Parkman-healthcare-partners
Longboard-pharmaceuticals-company-profile
Td-asset-management-inc
Cantor-fitzgerald
Analyst-recommendations-for-longboard-pharmaceuticals
Bourgeon-capital-management
News-ratings-for-longboard-pharmaceuticals-daily
Denali-advisors

Cantor Fitzgerald Reiterates "Overweight" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $60.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the stock’s current […]

Robertw-baird
Longboard-pharmaceuticals-company-profile
Td-asset-management-inc
Cantor-fitzgerald
Longboard-pharmaceuticals-stock-performance
Parkman-healthcare-partners
Longboard-pharmaceuticals
Jennison-associates
News-ratings-for-longboard-pharmaceuticals-daily
Longboard-pharmaceuticals-inc
Citigroup

Cantor Fitzgerald Reiterates "Overweight" Rating for Longboard Pharmaceuticals (NASDAQ:LBPH)

Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $60.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 178.68% from the stock’s current […]

Robertw-baird
Longboard-pharmaceuticals-stock-performance
Parkman-healthcare-partners
Longboard-pharmaceuticals
Jennison-associates
Longboard-pharmaceuticals-company-profile
Td-asset-management-inc
Cantor-fitzgerald
Platinum-investment-management-ltd
Analyst-recommendations-for-longboard-pharmaceuticals
News-ratings-for-longboard-pharmaceuticals-daily

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.